NEW YORK (360Dx) – Diaceutics this week announced a collaboration with Lenovo and Intel to leverage artificial intelligence to determine if patients can be grouped based on diagnostic test information.
By doing so, the partners believe the data can help identify ways of improving diagnosis, treatment, and outcomes for patients sharing similar characteristics.
The collaboration will leverage Diaceutics' proprietary database of patient testing data and use the Lenovo ThinkStation P920 workstation powered by Intel Xeon Scalable processors. Data from hundreds of clinical laboratories will be analyzed so that the right medicines cand be delivered to to the right patients at the right time by classifying patient groups and disease patterns, Diaceutics said.
Looking at biomarkers for a variety of tumors and cancer types, the machine learning system will identify similarities and patterns within the testing data, focusing on what is happening among groups of patients. The aim is to get a correct diagnosis for a patient and the right treatment more quickly.
"No longer will we only be making decisions based on diagnostic data," Diaceutics CEO Peter Keeling said in a statement. "Artificial intelligence allows us to look at the complete patient journey from initial testing and diagnosis, and on to the ultimate treatment. The result will be significantly better patient testing and likely improved patient outcomes, such as longer cancer survivorship rates."